BeiGene Switzerland GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.8M
Doctors Paid
11
Transactions
132
2024 Total
$799,534
Payment Breakdown by Category
Research$6.7M (97.5%)
Consulting$50,655 (0.7%)
Travel$17,498 (0.3%)
Food & Beverage$253.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.7M | 96 | 97.5% |
| Grant | $100,000 | 1 | 1.5% |
| Consulting Fee | $50,655 | 17 | 0.7% |
| Travel and Lodging | $17,498 | 7 | 0.3% |
| Food and Beverage | $253.36 | 11 | 0.0% |
Payments by Type
Research
$6.7M
96 transactions
General
$168,406
36 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Single-dose, Open-label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of a Zanubrutinib Tablet Compared to Zanubrutinib Capsules | $1.8M | 0 | 25 |
| A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress | $1.5M | 0 | 26 |
| A Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of a Zanubrutinib Tablet Compared to Zanubrutinib Capsules and to Evaluate the Effects of Food on the Pharmacokinetics of the Zanubrutinib Tablet | $843,276 | 0 | 10 |
| A Single-Dose, Open-Label, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of a Zanubrutinib 160 mg Tablet Compared to two 80 mg Capsules and to Evaluate the Effects of Food on the Pharmacokinetics of the Zanub | $802,236 | 0 | 14 |
| Retrospective evaluation of cytogenomic complexity by whole exome sequencing in treatment nave and | $550,000 | 0 | 1 |
| A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL/SLL Patients | $400,000 | 0 | 3 |
| ISR-CL-BGB3111-NonBGNE-0009 | $150,000 | 0 | 1 |
| Phase II, Single-arm, Open-label, Multicenter study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-cell therapy in Aggressive B-cell Non-Hogkins Lymphoma | $148,154 | 0 | 1 |
| A Single-dose, Open-label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of a Zanubrutinib 160 mg Tablet Compared to Two BRUKINSA (zanubrutinib) 80 mg Capsules | $118,056 | 0 | 4 |
| A Phase I Study of Cabozantinib and Pamiparib to Evaluate Triple Inhibition of PARP, VEGFR and c-MET in Advanced Homologous Recombination Deficient Malignancies | $80,000 | 0 | 2 |
| A Phase I Study of Cabozantinb and Pamiparib to Evaluate Triple Inhibition of PARP, VEGFR and c-MET in Advanced Homologous Recombination Deficient Malignancies | $79,774 | 0 | 2 |
| Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma | $67,741 | 0 | 1 |
| Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) | $56,320 | 0 | 1 |
| CRATER: ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer | $40,054 | 0 | 1 |
| ISR-CL-BGB290-NonBGNE-001 : 2020-0308 A Phase I Study of Cabozantinib and Pamiparib to Evaluate Triple Inhibition of PARP, VEGFR and c-MET in Advanced Homologous Recombination Deficient Malignancies | $40,000 | 0 | 1 |
| BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | $40,000 | 0 | 1 |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild-to-Moderate COVID-19 | $2,250 | 0 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma | $1,165 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology & Oncology | $42,895 | 4 | $10,724 |
| Specialist | $11,546 | 1 | $11,546 |
| Hematology | $7,895 | 2 | $3,947 |
| Medical Oncology | $4,425 | 2 | $2,213 |
| Internal Medicine | $1,646 | 2 | $822.78 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Matthew Davids, M.d, M.D | Hematology & Oncology | Boston, MA | $24,540 | $0 |
| Christopher Flowers, M.d, M.D | Hematology & Oncology | Houston, TX | $13,805 | $0 |
| Dr. Steven Treon, Md, Phd, MD, PHD | Specialist | Boston, MA | $11,546 | $0 |
| Jorge Castillo, Md, MD | Hematology | Boston, MA | $4,096 | $0 |
| Maria Palomba, Md, MD | Hematology | New York, NY | $3,799 | $0 |
| Marina Chiara Garassino, Md, MD | Hematology & Oncology | Chicago, IL | $2,925 | $0 |
| David Camidge, Md, MD | Medical Oncology | Aurora, CO | $2,800 | $0 |
| Dr. Sandip Patel, M.d, M.D | Hematology & Oncology | San Diego, CA | $1,625 | $0 |
| Dr. Brad Kahl, Md, MD | Medical Oncology | Saint Louis, MO | $1,625 | $0 |
| Justin Gainor, Md, MD | Internal Medicine | Boston, MA | $1,300 | $0 |
| Prashant Kapoor, Md, MD | Internal Medicine | Rochester, MN | $345.56 | $0 |
Ad
Top Products
- BRUKINSA $5.1M
- TEVIMBRA $1,500
Payment Categories
- Food & Beverage $253.36
- Consulting $50,655
- Travel & Lodging $17,498
- Research $6.7M
About BeiGene Switzerland GmbH
BeiGene Switzerland GmbH has made $6.8M in payments to 11 healthcare providers, recorded across 132 transactions in the CMS Open Payments database. In 2024, the company paid $799,534. The top product by payment volume is BRUKINSA ($5.1M).
Payments were distributed across 5 medical specialties. The top specialty by payment amount is Hematology & Oncology ($42,895 to 4 doctors).
Payment categories include: Food & Beverage ($253.36), Consulting ($50,655), Research ($6.7M), Travel & Lodging ($17,498).